157 related articles for article (PubMed ID: 10561619)
21. Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study.
Bristow CC; Larson E; Anderson LJ; Klausner JD
Sex Transm Infect; 2016 Aug; 92(5):340-6. PubMed ID: 26920867
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
23. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission.
Sansom SL; Jamieson DJ; Farnham PG; Bulterys M; Fowler MG
Obstet Gynecol; 2003 Oct; 102(4):782-90. PubMed ID: 14551009
[TBL] [Abstract][Full Text] [Related]
24. Perinatal screening for group B streptococci: cost-benefit analysis of rapid polymerase chain reaction.
Haberland CA; Benitz WE; Sanders GD; Pietzsch JB; Yamada S; Nguyen L; Garber AM
Pediatrics; 2002 Sep; 110(3):471-80. PubMed ID: 12205247
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
26. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States.
Zaric GS; Bayoumi AM; Brandeau ML; Owens DK
J Acquir Immune Defic Syndr; 2000 Dec; 25(5):403-16. PubMed ID: 11141240
[TBL] [Abstract][Full Text] [Related]
27. Perinatal HIV transmission and the cost-effectiveness of screening at 14 weeks gestation, at the onset of labour and the rapid testing of infants.
Udeh B; Udeh C; Graves N
BMC Infect Dis; 2008 Dec; 8():174. PubMed ID: 19117527
[TBL] [Abstract][Full Text] [Related]
28. Voluntary screening program for HIV in pregnancy. Cost effectiveness.
Rivera-Alsina ME; Rivera CC; Rollene N; Kirby RS; Ayres A; McNamara M
J Reprod Med; 2001 Mar; 46(3):243-8. PubMed ID: 11304866
[TBL] [Abstract][Full Text] [Related]
29. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population.
Lewis R; O'Brien JM; Ray DT; Sibai BM
Am J Obstet Gynecol; 1995 Oct; 173(4):1329-33. PubMed ID: 7485348
[TBL] [Abstract][Full Text] [Related]
30. Committee opinion no: 635: Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations.
Obstet Gynecol; 2015 Jun; 125(6):1544-1547. PubMed ID: 26000543
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of elective cesarean delivery in human immunodeficiency virus-infected women(1).
Chen KT; Sell RL; Tuomala RE
Obstet Gynecol; 2001 Feb; 97(2):161-8. PubMed ID: 11165575
[TBL] [Abstract][Full Text] [Related]
32. Experience with routine voluntary perinatal human immunodeficiency virus testing in an inner city hospital.
Henderson SL; Lindsay MK; Higgins JE; Clark WS; Bulterys M; Nesheim SR
Pediatr Infect Dis J; 2001 Nov; 20(11):1090-2. PubMed ID: 11734720
[TBL] [Abstract][Full Text] [Related]
33. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
Wilkinson D; Floyd K; Gilks CF
S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting.
Kim LH; Cohan DL; Sparks TN; Pilliod RA; Arinaitwe E; Caughey AB
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):195-200. PubMed ID: 23392461
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of option B+ in prevention of mother-to-child transmission of HIV in Yunnan Province, China.
Wang X; Guo G; Zheng J; Lu L
BMC Infect Dis; 2019 Jun; 19(1):517. PubMed ID: 31185927
[TBL] [Abstract][Full Text] [Related]
36. Preventing perinatal HIV transmission: zidovudine use during pregnancy.
Carmichael C
Am Fam Physician; 1997 Jan; 55(1):171-4, 177-8. PubMed ID: 9012276
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of universal prenatal HIV screening compared with current 'at risk' policy in a very low prevalence country.
Chowers M; Shavit O
Sex Transm Infect; 2017 Mar; 93(2):112-117. PubMed ID: 28213577
[TBL] [Abstract][Full Text] [Related]
38. The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model.
Kahn JG; Jiwani A; Gomez GB; Hawkes SJ; Chesson HW; Broutet N; Kamb ML; Newman LM
PLoS One; 2014; 9(1):e87510. PubMed ID: 24489931
[TBL] [Abstract][Full Text] [Related]
39. [The reduction of mother-child transmission of HIV infection in developing countries: potential intervention strategies, obstacles to implementation and perspectives. The Reduction of Mother-Child Transmission of HIV Infection in Africa Group].
Meda N; Msellati P; Welffens-Ekra C; Cartoux M; Leroy V; Van de Perre P; Salamon R
Sante; 1997; 7(2):115-25. PubMed ID: 9273118
[TBL] [Abstract][Full Text] [Related]
40. The cost effectiveness of universal antenatal screening for HIV in New Zealand.
Bramley D; Graves N; Walker D
AIDS; 2003 Mar; 17(5):741-8. PubMed ID: 12646798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
